Prostate inhibin peptide (PIP) in prostate cancer

a comparative immunohistochemical study with prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP)

Seema V. Garde, Anil R. Sheth, V. M. Venkatesan, Chandra J. Panchal, Arthur T. Porter, David Grignon

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Prostate inhibin peptide (PIP) is a polypeptide synthesized by the prostate gland that is involved in prostatic growth and differentiation. The objective of this study was to evaluate PIP as an immunocytochemical marker for prostatic adenocarcinoma (PCA) by comparing it with PSA and PAP. A total of 71 cases of primary PCA and 5 cases of metastatic PCA were studied. Primary tumors were specially selected to include a disproportionate number of high-grade tumors. The distribution of cases by Gleason score was 2-5, 14 cases; 6-7, 24 cases; and 8-10, 33 cases. Four metastases were to bone (decalcified tissue) and one to soft tissue. All 71 cases of primary PCA stained positively for the three antibodies tested, with none demonstrating obvious superiority, although individual case variability was seen. In one bone metastasis, staining for PSA was negative, with both PAP and PIP giving positive results. All non-prostatic carcinomas tested were negative. These results indicate that PIP is as sensitive and specific an immunohistochemical marker as PSA and PAP in untreated prostate adenocarcinomas. Further, the androgen-independent nature of PIP may give it an advantage over PSA PAP in tumors exposed to androgen ablating agents.

Original languageEnglish (US)
Pages (from-to)11-17
Number of pages7
JournalCancer Letters
Volume78
Issue number1-3
DOIs
StatePublished - Apr 1 1994
Externally publishedYes

Fingerprint

Inhibins
Prostate-Specific Antigen
Prostate
Prostatic Neoplasms
Peptides
Adenocarcinoma
Androgens
Neoplasm Metastasis
Bone and Bones
Neoplasms
Neoplasm Grading
prostatic acid phosphatase
Staining and Labeling
Carcinoma
Antibodies
Growth

Keywords

  • Immunohistochemistry
  • Peptide
  • Prostate cancer
  • Prostate inhibin

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Oncology

Cite this

Prostate inhibin peptide (PIP) in prostate cancer : a comparative immunohistochemical study with prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP). / Garde, Seema V.; Sheth, Anil R.; Venkatesan, V. M.; Panchal, Chandra J.; Porter, Arthur T.; Grignon, David.

In: Cancer Letters, Vol. 78, No. 1-3, 01.04.1994, p. 11-17.

Research output: Contribution to journalArticle

Garde, Seema V. ; Sheth, Anil R. ; Venkatesan, V. M. ; Panchal, Chandra J. ; Porter, Arthur T. ; Grignon, David. / Prostate inhibin peptide (PIP) in prostate cancer : a comparative immunohistochemical study with prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP). In: Cancer Letters. 1994 ; Vol. 78, No. 1-3. pp. 11-17.
@article{fd4a496fb5224e0f84ba8c550e402a4a,
title = "Prostate inhibin peptide (PIP) in prostate cancer: a comparative immunohistochemical study with prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP)",
abstract = "Prostate inhibin peptide (PIP) is a polypeptide synthesized by the prostate gland that is involved in prostatic growth and differentiation. The objective of this study was to evaluate PIP as an immunocytochemical marker for prostatic adenocarcinoma (PCA) by comparing it with PSA and PAP. A total of 71 cases of primary PCA and 5 cases of metastatic PCA were studied. Primary tumors were specially selected to include a disproportionate number of high-grade tumors. The distribution of cases by Gleason score was 2-5, 14 cases; 6-7, 24 cases; and 8-10, 33 cases. Four metastases were to bone (decalcified tissue) and one to soft tissue. All 71 cases of primary PCA stained positively for the three antibodies tested, with none demonstrating obvious superiority, although individual case variability was seen. In one bone metastasis, staining for PSA was negative, with both PAP and PIP giving positive results. All non-prostatic carcinomas tested were negative. These results indicate that PIP is as sensitive and specific an immunohistochemical marker as PSA and PAP in untreated prostate adenocarcinomas. Further, the androgen-independent nature of PIP may give it an advantage over PSA PAP in tumors exposed to androgen ablating agents.",
keywords = "Immunohistochemistry, Peptide, Prostate cancer, Prostate inhibin",
author = "Garde, {Seema V.} and Sheth, {Anil R.} and Venkatesan, {V. M.} and Panchal, {Chandra J.} and Porter, {Arthur T.} and David Grignon",
year = "1994",
month = "4",
day = "1",
doi = "10.1016/0304-3835(94)90025-6",
language = "English (US)",
volume = "78",
pages = "11--17",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1-3",

}

TY - JOUR

T1 - Prostate inhibin peptide (PIP) in prostate cancer

T2 - a comparative immunohistochemical study with prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP)

AU - Garde, Seema V.

AU - Sheth, Anil R.

AU - Venkatesan, V. M.

AU - Panchal, Chandra J.

AU - Porter, Arthur T.

AU - Grignon, David

PY - 1994/4/1

Y1 - 1994/4/1

N2 - Prostate inhibin peptide (PIP) is a polypeptide synthesized by the prostate gland that is involved in prostatic growth and differentiation. The objective of this study was to evaluate PIP as an immunocytochemical marker for prostatic adenocarcinoma (PCA) by comparing it with PSA and PAP. A total of 71 cases of primary PCA and 5 cases of metastatic PCA were studied. Primary tumors were specially selected to include a disproportionate number of high-grade tumors. The distribution of cases by Gleason score was 2-5, 14 cases; 6-7, 24 cases; and 8-10, 33 cases. Four metastases were to bone (decalcified tissue) and one to soft tissue. All 71 cases of primary PCA stained positively for the three antibodies tested, with none demonstrating obvious superiority, although individual case variability was seen. In one bone metastasis, staining for PSA was negative, with both PAP and PIP giving positive results. All non-prostatic carcinomas tested were negative. These results indicate that PIP is as sensitive and specific an immunohistochemical marker as PSA and PAP in untreated prostate adenocarcinomas. Further, the androgen-independent nature of PIP may give it an advantage over PSA PAP in tumors exposed to androgen ablating agents.

AB - Prostate inhibin peptide (PIP) is a polypeptide synthesized by the prostate gland that is involved in prostatic growth and differentiation. The objective of this study was to evaluate PIP as an immunocytochemical marker for prostatic adenocarcinoma (PCA) by comparing it with PSA and PAP. A total of 71 cases of primary PCA and 5 cases of metastatic PCA were studied. Primary tumors were specially selected to include a disproportionate number of high-grade tumors. The distribution of cases by Gleason score was 2-5, 14 cases; 6-7, 24 cases; and 8-10, 33 cases. Four metastases were to bone (decalcified tissue) and one to soft tissue. All 71 cases of primary PCA stained positively for the three antibodies tested, with none demonstrating obvious superiority, although individual case variability was seen. In one bone metastasis, staining for PSA was negative, with both PAP and PIP giving positive results. All non-prostatic carcinomas tested were negative. These results indicate that PIP is as sensitive and specific an immunohistochemical marker as PSA and PAP in untreated prostate adenocarcinomas. Further, the androgen-independent nature of PIP may give it an advantage over PSA PAP in tumors exposed to androgen ablating agents.

KW - Immunohistochemistry

KW - Peptide

KW - Prostate cancer

KW - Prostate inhibin

UR - http://www.scopus.com/inward/record.url?scp=0028270382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028270382&partnerID=8YFLogxK

U2 - 10.1016/0304-3835(94)90025-6

DO - 10.1016/0304-3835(94)90025-6

M3 - Article

VL - 78

SP - 11

EP - 17

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1-3

ER -